Newsletter Tool

To view this email as a web page, click here

Today's Rundown

What doctors need to know about the Johnson & Johnson COVID-19 vaccine pause
Pfizer, BioNTech amp up mRNA vaccine delivery targets amid Johnson & Johnson's delays
White House won't buy more Pfizer, Moderna COVID-19 vaccine shots after J&J pause
New approaches to AI, cell biology may have uncovered a novel drug target for COVID-19: Humans themselves
Europe won't renew AstraZeneca, Johnson & Johnson COVID-19 vaccine contracts next year: report
COVID-19 tracker: CDC panel reviews J&J vaccine data; Pfizer prices going up in Europe
UPDATED Coronavirus tracker: Former CDC director advises controversial air purification company
Moderna advancing early stage mRNA prospects to show depth beyond COVID-19 shot
BioAge picks up muscle-aging program from Amgen, bringing pipeline count to 3

Featured Story

What doctors need to know about the Johnson & Johnson COVID-19 vaccine pause

By Heather Landi

While the rare blood clot cases associated with Johnson & Johnson's COVID-19 vaccine only involve six cases, pausing the vaccine's rollout is necessary out of an abundance of caution, Peter Marks with the FDA said. "We don’t have a lot of tolerance for friendly fire," he said. Here's what doctors need to know about signs or symptoms of a potential adverse reaction to the J&J vaccine.

Pfizer, BioNTech amp up mRNA vaccine delivery targets amid Johnson & Johnson's delays

By Kevin Dunleavy

With Johnson & Johnson's COVID-19 vaccine under scrutiny in the U.S. and the company pausing shipments to Europe, Pfizer and BioNTech have stepped in to boost supply commitments on both sides of the Atlantic.

White House won't buy more Pfizer, Moderna COVID-19 vaccine shots after J&J pause

By Robert King

White House officials said they won't procure more doses of Moderna or Pfizer's COVID-19 vaccine in response to a pause of J&J's vaccine rollout while the FDA investigates rare blood clot cases.

New approaches to AI, cell biology may have uncovered a novel drug target for COVID-19: Humans themselves

By Conor Hale

By combining artificial intelligence and an extensive atlas of protein biology, Cyclica is taking new approaches to searching for old drugs that could fight COVID-19—and, now, it’s helped find what could become a first-in-class candidate.

Europe won't renew AstraZeneca, Johnson & Johnson COVID-19 vaccine contracts next year: report

By Fraiser Kansteiner

As Johnson & Johnson and AstraZeneca's COVID-19 vaccines grapple with safety concerns and delivery delays in Europe, the bloc has opted not to renew its supply contracts with companies next year, an Italian newspaper first reported.

COVID-19 tracker: CDC panel reviews J&J vaccine data; Pfizer prices going up in Europe

By Noah Higgins-Dunn,Fraiser Kansteiner,Eric Sagonowsky

Johnson & Johnson's COVID-19 vaccine is under review at an independent vaccine committee of the CDC, which is reviewing data and will make recommendations about how to proceed. Plus, headlines from Pfizer and AstraZeneca.

UPDATED Coronavirus tracker: Former CDC director advises controversial air purification company

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Moderna advancing early stage mRNA prospects to show depth beyond COVID-19 shot

By Annalee Armstrong

Moderna, armed with cash from the development of its COVID-19 vaccine, is advancing several other mRNA vaccine candidates in the clinic to show the biotech has more to offer than just the shot that made them world famous.

BioAge picks up muscle-aging program from Amgen, bringing pipeline count to 3

By Amirah Al Idrus

BioAge Labs is adding a third program to its pipeline. The new treatment, licensed from Amgen, is designed to combat muscle aging and could be useful in helping older people recover from surgery more quickly, decreasing muscle atrophy after a long hospital stay, or eventually, warding off frailty in older people.

COVID-19 Tracker